146 related articles for article (PubMed ID: 27805921)
1. c-CBL E3 Ubiquitin Ligase Expression Increases Across the Spectrum of Benign and Malignant T-Cell Skin Diseases.
Salva KA; Reeder MJ; Lloyd R; Wood GS
Am J Dermatopathol; 2017 Oct; 39(10):731-737. PubMed ID: 27805921
[TBL] [Abstract][Full Text] [Related]
2. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of c-myb in leukaemic and non-leukaemic variants of cutaneous T-cell lymphoma.
Poenitz N; Simon-Ackermann J; Gratchev A; Qadoumi M; Klemke CD; Stadler R; Kremer A; Radenhausen M; Henke U; Assaf C; Utikal J; Goerdt S; Dippel E
Dermatology; 2005; 211(2):84-92. PubMed ID: 16088151
[TBL] [Abstract][Full Text] [Related]
4. c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death.
Wu J; Salva KA; Wood GS
J Invest Dermatol; 2015 Mar; 135(3):861-868. PubMed ID: 25140833
[TBL] [Abstract][Full Text] [Related]
5. Expression of the Voltage-Gated Potassium Channel Kv1.3 in Lesional Skin from Patients with Cutaneous T-Cell Lymphoma and Benign Dermatitis.
Hu T; Krejsgaard T; Nastasi C; Buus TB; Nansen A; Hald A; Spee P; Nielsen PR; Blümel E; Gluud M; Willerslev-Olsen A; Woetmann A; Bzorek M; Eriksen JO; Ødum N; Rahbek Gjerdrum LM
Dermatology; 2020; 236(2):123-132. PubMed ID: 31536992
[TBL] [Abstract][Full Text] [Related]
6. Silencing autocrine death: a ubiquitin ligase that blocks activation-induced cell death in cutaneous T-cell lymphoma.
Klemke CD; Feoktistova M; Leverkus M
J Invest Dermatol; 2015 Mar; 135(3):662-665. PubMed ID: 25666675
[TBL] [Abstract][Full Text] [Related]
7. TOX expression in different subtypes of cutaneous lymphoma.
Morimura S; Sugaya M; Suga H; Miyagaki T; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Arch Dermatol Res; 2014 Nov; 306(9):843-9. PubMed ID: 25216799
[TBL] [Abstract][Full Text] [Related]
8. Toll-like receptors 2, 4 and 9 expression in cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome).
Jarrousse V; Quereux G; Marques-Briand S; Knol AC; Khammari A; Dreno B
Eur J Dermatol; 2006; 16(6):636-41. PubMed ID: 17229603
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma.
Ralfkiaer U; Lindahl LM; Litman T; Gjerdrum LM; Ahler CB; Gniadecki R; Marstrand T; Fredholm S; Iversen L; Wasik MA; Bonefeld CM; Geisler C; Krejsgaard T; Glue C; Røpke MA; Woetmann A; Skov L; Grønbæk K; Odum N
Anticancer Res; 2014 Dec; 34(12):7207-17. PubMed ID: 25503151
[TBL] [Abstract][Full Text] [Related]
10. Expression of helper T cell master regulators in inflammatory dermatoses and primary cutaneous T-cell lymphomas: diagnostic implications.
Hsi AC; Lee SJ; Rosman IS; Carson KR; Kelley A; Viele V; Pang X; Musiek A; Schaffer A
J Am Acad Dermatol; 2015 Jan; 72(1):159-67. PubMed ID: 25440432
[TBL] [Abstract][Full Text] [Related]
11. Expression of MCM-3 and MCM-7 in Primary Cutaneous T-cell Lymphomas.
Jankowska-Konsur A; Kobierzycki C; Reich A; Grzegrzolka J; Maj J; Dziegiel P
Anticancer Res; 2015 Nov; 35(11):6017-26. PubMed ID: 26504025
[TBL] [Abstract][Full Text] [Related]
12. Upregulation of inhibitory signaling receptor programmed death marker-1 (PD-1) in disease evolution from cutaneous lymphoid dyscrasias to mycosis fungoides and Sezary's syndrome.
Nguyen GH; Olson LC; Magro CM
Ann Diagn Pathol; 2017 Jun; 28():54-59. PubMed ID: 28648940
[TBL] [Abstract][Full Text] [Related]
13. Telomerase functions beyond telomere maintenance in primary cutaneous T-cell lymphoma.
Chevret E; Andrique L; Prochazkova-Carlotti M; Ferrer J; Cappellen D; Laharanne E; Idrissi Y; Boettiger A; Sahraoui W; Ruiz F; Pham-Ledard A; Vergier B; Belloc F; Dubus P; Beylot-Barry M; Merlio JP
Blood; 2014 Mar; 123(12):1850-9. PubMed ID: 24470590
[TBL] [Abstract][Full Text] [Related]
14. PAK1 overexpression promotes cell proliferation in cutaneous T cell lymphoma via suppression of PUMA and p21.
Wang Y; Gu X; Li W; Zhang Q; Zhang C
J Dermatol Sci; 2018 Apr; 90(1):60-67. PubMed ID: 29307600
[TBL] [Abstract][Full Text] [Related]
15. High numbers of DC-SIGN+ dendritic cells in lesional skin of cutaneous T-cell lymphoma.
Schlapbach C; Ochsenbein A; Kaelin U; Hassan AS; Hunger RE; Yawalkar N
J Am Acad Dermatol; 2010 Jun; 62(6):995-1004. PubMed ID: 20466174
[TBL] [Abstract][Full Text] [Related]
16. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
17. CCR4 is expressed on infiltrating cells in lesional skin of early mycosis fungoides and atopic dermatitis.
Sugaya M; Morimura S; Suga H; Kawaguchi M; Miyagaki T; Ohmatsu H; Fujita H; Sato S
J Dermatol; 2015 Jun; 42(6):613-5. PubMed ID: 25809616
[TBL] [Abstract][Full Text] [Related]
18. TOX expression in cutaneous T-cell lymphomas: an adjunctive diagnostic marker that is not tumour specific and not restricted to the CD4(+) CD8(-) phenotype.
Schrader AM; Jansen PM; Willemze R
Br J Dermatol; 2016 Aug; 175(2):382-6. PubMed ID: 26931394
[TBL] [Abstract][Full Text] [Related]
19. High expression of Dicer reveals a negative prognostic influence in certain subtypes of primary cutaneous T cell lymphomas.
Valencak J; Schmid K; Trautinger F; Wallnöfer W; Muellauer L; Soleiman A; Knobler R; Haitel A; Pehamberger H; Raderer M
J Dermatol Sci; 2011 Dec; 64(3):185-90. PubMed ID: 21937200
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of IkappaB kinase subunit 2 in cutaneous T-cell lymphoma down-regulates nuclear factor-kappaB constitutive activation, induces cell death, and potentiates the apoptotic response to antineoplastic chemotherapeutic agents.
Sors A; Jean-Louis F; Bégué E; Parmentier L; Dubertret L; Dreano M; Courtois G; Bachelez H; Michel L
Clin Cancer Res; 2008 Feb; 14(3):901-11. PubMed ID: 18245554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
